drugset

drugset / Trial / NCT07104201

Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)

NCT07104201 ↗

Phase 0 Recruiting 15 enrolled Xijing Hospital of Digestive Diseases

NaSingle-groupOpen-labelTreatment

Summary

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Fenofibrate in Subjects with Primary Biliary Cholangitis (PBC)

Timeline

Start: 2025-03-13
Primary completion: 2035-03
Completion: 2035-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fenofibrate	Small molecule	200 mg	—

Indications